Acutaas Chemicals Ltd vs Alivus Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 2596 as of 30 Apr 15:30 . The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Acutaas Chemicals Ltd for the Mar '26 is ₹ 443.86 crore as compare to the Dec '25 revenue of ₹ 397.88 crore. This represent the growth of 11.56% The revenue of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Acutaas Chemicals Ltd for the Mar '26 is ₹ 194.62 crore as compare to the Dec '25 ebitda of ₹ 155.35 crore. This represent the growth of 25.28% The ebitda of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Acutaas Chemicals Ltd changed from ₹ 14.69 crore to ₹ 134.28 crore over 8 quarters. This represents a CAGR of 202.34% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 years .

About Acutaas Chemicals Ltd

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India.
The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018.
The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies. The Company is engaged in business of drugs intermediate chemicals and related activities.
The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

FAQs for the comparison of Acutaas Chemicals Ltd and Alivus Life Sciences Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or Alivus Life Sciences Ltd?

Market cap of Acutaas Chemicals Ltd is 21,258 Cr while Market cap of Alivus Life Sciences Ltd is 12,733 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and Alivus Life Sciences Ltd?

The stock performance of Acutaas Chemicals Ltd and Alivus Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and Alivus Life Sciences Ltd?

As of May 4, 2026, the Acutaas Chemicals Ltd stock price is INR ₹2596.55. On the other hand, Alivus Life Sciences Ltd stock price is INR ₹1037.5.

How do dividend payouts of Acutaas Chemicals Ltd and Alivus Life Sciences Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and Alivus Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.